Derma Pharma Pty Ltd (Derma Pharma) is a specialty pharmaceutical company with a focus on bridging gaps in the treatment of the top 3 most prevalent skin diseases globally – acne, psoriasis and eczema.

​

Core Focus: Addressing unmet medical needs in dermatological conditions, initially targeting acne, which affects 9.4% of the global population. An acne range will be launched in Q1 Year 2 in the Australian/New Zealand markets followed by the USA, Europe, and Japan. 

Future skin solutions will be focused on psoriasis and eczema.

​

Innovative Technology: Leveraging our proprietary ALGAVIO ingredient to innovate and revolutionize acne treatments. Acne ranks as the eighth most prevalent disease worldwide, offering a significant market opportunity. Psoriasis and eczema products will follow the successful launch of the acne range.

"ALGAVIO innovates and revolutionises acne treatments."

 

Capital Raise and Exit Strategy

Derma Pharma is conducting a Seed Round raising $1.2m at 50c per share for 30% ownership of the business. Funds will be used to conduct the necessary Research & Development to test and formulate the initial acne range and develop the market entry strategy.

 

We plan to build the business to a stage where a Trade Sale or an IPO on either the ASX, TSX or AIM is possible within a 4 – 5 year period.